Tag - INDP

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Developments

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

Indaptus Therapeutics (NASDAQ:INDP) initiated INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound, Decoy20, in patients with...

December 13, 2022

Markets

Maxim ups Indaptus Therapeutics to buy from hold; PT $16

Maxim Group upgraded Indaptus Therapeutics (NASDAQ:INDP) to a “buy” rating from “hold” with a price target of $16, based on the potential of lead oncology program Decoy20 in pancreatic, liver and colorectal cancers as...

October 19, 2021

Tag - INDP

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

Maxim ups Indaptus Therapeutics to buy from hold; PT $16

General

More